Aug 1 |
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
|
Aug 1 |
Moderna: Q2 Earnings Snapshot
|
Aug 1 |
Moderna GAAP EPS of -$3.33 beats by $0.02, revenue of $241M beats by $106.13M
|
Aug 1 |
Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue
|
Aug 1 |
Moderna Cuts Revenue Guidance Amid Steeper Competition
|
Aug 1 |
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
Jul 31 |
Moderna Q2 Earnings Preview: Focus on RSV vaccine despite downbeat expectations
|
Jul 31 |
Leveragen and Moderna link to advance therapeutics
|
Jul 30 |
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
|
Jul 30 |
Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
|